The Problem
-
Dengue virus (DENV) remains a major public health burden and until recently, no vaccine was available
-
The approved dengue vaccine is based on live-attenuated virus; however, it is not recommended for use in all populations
-
A non-infectious variant of DENV could provide a starting point for an improved next-generation vaccine that would reach more people at risk
The Solution
Atomic-level functional model of dengue virus Envelope protein infectivity
-
We made and screened 1,433 mutations.spanning the DENV3 envelope protein (prM/E)
-
Analysis of DENV3 Env ectodomain mutations identified variants with high expression and high ability to bud, yet low/no infectivity
The Impact
-
We identified non-infectious variants that showed no signs of structural impairment (i.e., wild-type levels of expression, antibody reactivity, and release of intact virions)
-
Such non-infectious variants can be valuable in the design of vaccines with improved availability to at-risk populations
Harness Integral Molecular’s 20+ years of protein engineering experience to improve gene therapy using GeneCanvas
Integral Molecular does not work with any live viruses capable of causing infectious disease. We have developed Reporter Virus Particles (RVPs) to enable scientists to study infectivity and viral components without the risk of exposure to viruses or the spread of contagious illnesses.